The New York Times @nytimes
Since the technology for bespoke genetic drugs debuted, about two dozen patients have received the infusions — costing as much as $2 million per patient. But hundreds of millions of others live with rare genetic diseases and have no treatment options. https://t.co/VWGj0qymqh — PolitiTweet.org